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INTRODUCTION
Polycystic ovary syndrome (PCOs) is an endocrine
disorder mostly found in women of reproductive age,
marked by the combination of several clinical mani-
festations such as hyperandrogenism, oligo-/amenor-
rhea, oligo-/anovulation, hirsutism, specific ovarian
morphology, hyperinsulinemia, and insulin resistan-
ce.1-4 In 1935, Stein and Leventhal for the first time
elucidated the relationship between bilateral polycys-
tic ovaries with amenorrhea, oligomenorrhea, hirsu-
tism, obesity in women whom ovaries hypertrophy
with multiple cystic follicles, and fibrotic thickening
of the tunica albuginea and cortical stroma. Nonethe-
less, the clinical feature and pathology of polycystic
or micropolycystic ovaries had been described by An-
tonio Vallisneri in 1721.5 The term PCOs was first
used in 1960 since both of clinical and histological
differences of this syndrome was identified. Since
1960, ovarian enlargement or the presence of histo-
logical anomaly from specimen biopsy became im-
portant considerations for diagnosis.
Abstract
Objective: To identify insulin resistance on PCOs patients and
to know characteristics and clinical differences between PCOs pa-
tients with and without insulin resistance in Gynecologic Outpatient
Clinic of H. Adam Malik Hospital, Clinic of Prof. Delfi Lutan,
Clinic of Prof. Thamrin Tanjung and Clinic of Halim Fertility Cen-
ter in Medan.
Method: This descriptive cross sectional study conducted from
July 2008 - June 2009, diagnosis of PCOs based on Rotterdam’s cri-
teria was drawn for 5 ml blood samples, from mediana cubiti vein,
after 10 - 12 hours fasting for determination of fasting glucose, fast-
ing insulin, LH, FSH, prolactin and testosterone. Insulin resistance
was determined by glucose/insulin fasting ratio < 4.5.
Result: From sixty one patients were divided into PCOs without
insulin resistance (50 patients; 82%) and PCOs with insulin resis-
tance (11 patients; 18%) group. No significant differences in
clinico-biochemical characteristics, fasting glucose mean level,
menstrual pattern, ovary volume, follicle number and reproductive
hormone profile of two groups, except in BMI value, fasting insulin
level and G:I ratio (p < 0.05).
Conclusion: There was significant correlation between fasting
insulin level and insulin resistance with mean of fasting insulin level
of 24.882 μU/ml. Insulin resistance was frequent on overweight
group study according to WHO criteria (BMI 25 - 29.9 kg/m2).
[Indones J Obstet Gynecol 2011; 35-2: 74-8]
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Abstrak
Tujuan: Untuk mengidentifikasi resistensi insulin, perbedaan
karakteristik dan klinis penderita SOPK dengan resistensi insulin
dibandingkan dengan penderita SOPK tanpa resistensi insulin di
Poliklinik Ginekologi RS H. Adam Malik dan Klinik Halim Fertility
Center, Medan.
Metode: Penelitian ini merupakan penelitian deskriptif dengan
rancangan potong lintang dari Juli 2008 - Juni 2009. Pasien yang
didiagnosa SOPK berdasarkan kriteria Rotterdam diinstruksikan
untuk berpuasa selama 10 - 12 jam semalam sebelum darah untuk
sampel penelitian diambil. Diambil darah pasien yang telah di-
puasakan sebanyak 5 cc dari vena mediana cubiti untuk dilakukan
pemeriksaan kadar glukosa puasa, kadar insulin puasa, kadar LH,
FSH, prolaktin, testosteron. Resistensi insulin ditandai dengan ra-
sio glukosa insulin puasa (Rasio G:I) < 4,5.
Hasil: Dari 61 pasien dibagi atas 2 kelompok yaitu SOPK tanpa
resistensi insulin (50 pasien, 82%) dan SOPK dengan resistensi in-
sulin (11 pasien, 18%). Tidak terdapat perbedaan bermakna dalam
hal karakteristik klinikobiokimia, kadar rata-rata glukosa puasa,
pola menstruasi, volume ovarium, jumlah folikel dan profil hormone
reproduksi dari kedua kelompok, kecuali pada nilai IMT, kadar in-
sulin puasa, rasio G:I (p < 0,05).
Kesimpulan: Terdapat hubungan yang bermakna antara kadar
insulin puasa terhadap terjadinya resistensi insulin dengan nilai
mean kadar insulin puasa 25,386 μU/ml. Frekuensi terbanyak resis-
tensi insulin pada penelitian ini ada pada kelompok dengan berat
badan berlebih, menurut kriteria WHO. (BMI 25 - 29,9 kg/m2).
[Maj Obstet Ginekol Indones 2011; 35-2: 74-8]
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Considering that the elevation of serum LH con-
centration and the increase of LH/FSH ratio are char-
acteristics of this syndrome, the examination of serum
gonadotrophin profile is an alternative approach to di-
agnose.
In 1970, the advance of ultrasound technology en-
abled non-invasive examination of ovarian morpho-
logy, which made possible visualization of a chariot
wheel image with 12 or more follicles.6
The relationship between carbohydrate metabolic
disorder and hyperandrogenism was explained in
1921 by Archard and Thiers.7 Subsequently, numer-
ous researches ascertained the relationship between
hyperinsulinemia and hyperandrogenism.8,9 In 1980,
Burgen et al reported that women with PCOs exhi-
biting hyperinsulinemia were attributed to insulin re-
sistance. The observation of this significant relation-
ship between insulin and androgen levels strengthens
the hypothesis of an etiologic relationship between
these two conditions.10 Furthermore, it is established
that women with PCOs have hyperinsulinemia when
compared with control based on age and body
weight.11-15 Consequently, 20% of women with PCOs
tested with OGTT showed impaired glucose tolerance
(IGT).16
Currently, it is well-accepted that obese women
with PCOs have insulin resistance. Whether it is
wholly attributable to PCOs or initially dependent on
body weight or body fat distribution is still open to
debate.12 Although insulin resistance is not a disease,
it is found in 50 - 70% of women with PCOs and is
correlated with increased risk of cardiovascular dis-
ease and type-2 diabetes mellitus. That weight reduc-
tion in obese PCOs patients, especially reduced adi-
posity in the abdomen, normalizes insulin sensitivity,
gives the impression that body fat distribution is an
important determinant of insulin resistance in PCOs.17
Insulin resistance in PCOs is correlated with ele-
vated level of androgen, particularly free testoste-
rone.4,7,9 Large doses of testosterone administered to
healthy women may trigger insulin resistance. Never-
the less, the interaction between hyperandrogenemia
and the definite etiology of insulin resistance remains
undetermined.17
The cause of hyperinsulinemia in women with PCOs
likewise remains unknown. This may be associated with
increased insulin serine phosphorylation receptors which
reduce the activity of tyrosine kinase protein and cause
post-binding defect of insulin effect and/or abnormal in-
sulin secretion. Metabolic disorder in PCOs may origi-
nate from early life, during the prenatal or prepubertal
period; early exposure to androgen during the develop-
mental phase of life may affect body fat distribution and
work of insulin. Clinical implications to women with
PCOs encompass the emergence of insulin resistance
and/or hyperinsulinemia, especially in groups with an-
ovulatory cycles and central obesity.17
Many earlier studies revealed that agents that im-
prove insulin resistance and reduce circulating insulin
level such as Troglitazone or Metformin may be new
approaches to treating PCOs. Therefore, recognizing
women with concomitant PCOs and severe insulin re-
sistance using simple tests has become a relevant me-
dical intervention that may improve insulin sensitivity
in PCOs patients.17
Until now, the latest data of insulin resistance on
PCOs patients in Indonesia as generally and newer
data in Medan as specifically are still lacked. There-
fore the author feels inclined to investigate this phe-
nomenon.
METHOD
This research is an analytic descriptive study with
cross-sectional approach conducted in the Department
of Obstetrics and Gynecology of H. Adam Malik Ge-
neral Hospital and private practice in Medan from
July 2008 until June 2009. Sixty-one female patients
suffering from PCOs, and which fulfilled inclusion
criteria, were designated as study subjects. They were
divided into two groups, PCOs patients without insu-
lin resistance and PCOs patients with insulin resis-
tance group. Data were analyzed using Chi-square and
Mann-Whitney U statistical test (SPSS version 15).
RESULTS
Distribution of study participants
Table 1. Distribution of study participants.
Group Frequency (n) Percentage (%)
Group of PCOs patients
without insulin resistance
50 82.0




Clinical and biochemical characteristics, Carbohy-
drate metabolism profile, Reproductive Hormone Pro-
file of group of PCOs patients without insulin resis-
tance and with insulin resistance.
BMI parameters according WHO criteria, Men-
strual cycle pattern, Ovarian volume, Number of fol-
licles of group of PCOs patients without insulin re-
sistance and with insulin resistance.
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DISCUSSION
In this study, it was found that group of PCOs patients
without insulin resistance was the majority of group
(82.0%) compared to group of PCOs patients with in-
sulin resistance (18.0%).
Meirow et al. reported that insulin resistance emer-
ged in 50% of PCOs patients of their study.18
Dunaif et al. and Legro et al. in their study reported
that the prevalence of insulin resistance varied bet-
ween 25 - 70% depending on ethnicity and method
of diagnosis.19,20
Meanwhile, Setiawan in the prior study in Medan
reported that the prevalence of insulin resistance was
17.1%.21
No significant differences were found in both
groups for clinical and biochemical characteristics,
except for Body Mass Index (BMI). The BMI in the
group of PCOs patients with resistance (27 kg/m2)
was greater compared to BMI in group of PCOs pa-
tients without insulin resistance (22.92 kg/m2).
From the carbohydrate metabolism profile, no sig-
nificant differences were found in both groups in
Table 2. Clinical and biochemical characteristics, Carbohydrate metabolism profile, Reproductive Hormone Profile of group of PCOs
patients without insulin resistance and with insulin resistance.
Group of PCOs patients
without insulin resistance
n = 50 (mean)
SD
Group of PCOs patients
with insulin resistance
n = 11 (mean)
SD p
Characteristic:
• Age (years) 27.8 3.5 30.5 6.0 0.127
• BMI (kg/m2) 22.9 3.0 27  3.8 0.002
• LH/FSH  1.3 0.9  1.3 0.8 0.771
• Testosterone (ng/dl)  0.7 0.3  0.7 0.3 0.754
• Prolactin (ng/ml) 15.9 5.4 12.5 3.3 0.082
• Menarche (years) 12.3 1.2 12.3 0.8 0.702
Carbohydrate Metabolism Profile:
• Blood sugar level (mg/dl) 84.9 9.8 88.1 4.4 0.239
• Fasting insulin level (μU/ml)  7.1 3.4 24.8 6.7 0.001
• G:I ratio 15.1 8.6  3.7 0.6 0.001
Reproductive Hormone Profile:
• LH (IU/ml)  7.6 6.4  6.6 3.5 0.955
• FSH  5.2 1.1  5.2 1.0 0.969
• LH/FSH  1.3 0.9  1.3 0.8 0.771
Mann-Whitney U test
Table 3. BMI parameters according WHO criteria, Menstrual cycle pattern, Ovarian volume, Number of follicles of group of PCOs
patients without insulin resistance and with insulin resistance.









• < 18.5 1  2.0  0   0  0.004
• 18.5 - 24.9 39 78.0  3  27.3
• 25 - 29.9 9 18.0  6  54.5
• > 30 1  2.0  2  18.2
Menstrual cycle pattern
• Amenorrhea 24 48.0  5  47.5 0.878
• Oligomenorrhea 26 52.0  6  52.5
Ovarian volume
• < 20 2  4.0  0   0  0.792
• 20 - 29 21 42.0  5  45.5
• > 30 27 54.0  6  54.5
Number of follicles
• 24 - 50 9 18.0  0   0  0.127
• ≥ 50 41 82.0 11 100  
Chi-square test
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mean blood sugar level; group without insulin resis-
tance (84.96 mg/dl) whereas group with insulin resis-
tance (88.18 mg/dl).
Fasting glucose level in the group without insulin
resistance ranged from 1.9 μU/ml to 16.5 μU/ml, with
mean 7.192 μU/ml. In the group of PCOs patients
with insulin resistance, fasting glucose level ranged
from 18.8 μU/ml to 43.3 μU/ml. Two subjects had
fasting glucose level < 20 μU/ml. Five subjects had
fasting glucose level of 20 - 25 μU/ml, while four
had levels > 25 μU/ml. Mean fasting glucose level
for this group was 24.882 μU/ml. There was a sig-
nificant difference of two groups using Mann-Whit-
ney U test (p = 0.001).
In this study, mean of G:I ratio for the group of
PCOs patients without insulin resistance was 15.152.
In the group of PCOs patients with insulin resistance,
mean of G:I ratio was 3.709. Significant differences
were found between the two groups (p = 0.001).
Legro et al. in their study predicted insulin resis-
tance in PCOs patients based on fasting glucose level
of > 20 μU/ml, whereas Acien et al. and Gennarelli
et al. in their studies reported that level of fasting
glucose level > 30 μU/ml was usually associated with
insulin resistance in PCOs patients.22-24
Castracane et al. in their study reported that fasting
glucose level > 20 μU/ml in Caucasian women and
fasting glucose level > 23 μU/ml in Mexican-Ameri-
can women may indicate insulin resistance in women
with PCOs.25
Setiawan in his study reported that mean fasting
glucose level in insulin resistance group was 25.386
μU/ml and G:I ratio was 3.701.21
In the group of PCOs patients with insulin resis-
tance, most of subjects were overweight with BMI 25
- 29.9 kg/m2 (6 patients; 54.5%). Significant differ-
ences were found between two groups, using Chi-
square test (p = 0.004).
BMI of ≥ 25 kg/m2 is one of the criteria of the
American Association of Clinical Endocrinologists to
diagnose insulin resistance.
In Medan, Setiawan reported that most of PCOs
patients with insulin resistance (42.9%) had BMI of
25 - 29.9 kg/m2.21
Ferrannini et al. obtained data from the European
Group for the Study of Insulin Resistance (EGIR) for
the prevalence of hyperinsulinemia dan insulin resis-
tance (IR) according based on BMI as the following:
From BMI parameters according to WHO, the preva-
lence of both hyperinsulinemia and insulin resistance
of BMI < 25 kg/m2 was 10%; BMI 25 - 28 kg/m2,
the prevalence of hyperinsulinemia was 30% while
the prevalence of insulin resistance was 12%; BMI
29 - 37 kg/m2 the corresponding prevalence was 48%
and 35%; and BMI > 37 kg/m2 the corresponding
prevalence was 80% and 60%.4,6
Holte et al. in their study established that insulin
resistance was mostly found in PCOs patients of
European women with BMI of 28 kg/m2 or more.26
Based on menstrual cycle pattern, oligomenorrhea
was the mostly menstrual pattern in both groups, 26
subjects (52.0%) in the group of PCOs patients with-
out insulin resistance whereas 6 subjects (52.5%) in
the group of PCOs patients with insulin resistance.
Analysis with Chi-square did not produce any signifi-
cant difference (p = 0.839).
Dunaif et al. and Robinsen et al. reported signifi-
cant differences of insulin sensitivity between PCOs
patients with anovulatory cycles and those with ovu-
latory cycles. PCOs patients with anovulatory cycles
showed insulin resistance while PCOs patients with
regular menstrual cycles did not.19,27
Abbott et al. concluded that there was a strong cor-
relation between menstrual cycle irregularity and in-
sulin resistance in PCOs women.28
Setiawan found that oligomenorrhea menstrual cy-
cle pattern was the most menstrual pattern in PCOs
patients without insulin resistance (52.9%) also in
PCOs patients with insulin resistance, the prevalence
was 57.1%.21
Ovarian volume in each study group. Chi-square
analysis yielded no significant difference in terms of
ovarian volume, with p = 0.792. Ovarian volume ex-
ceeding 30 ml formed the highest frequency.
The number of follicles from each group. Within
the group of PCOs patients with insulin resistance
were found 11 subjects (100%) with follicles totaling
50 or more. Meanwhile, in the group without insulin
resistance, 41 subjects (82.0%) had 50 or more folli-
cles. Chi-square analysis yielded no significant differ-
ence (p = 0.127) notwithstanding, there existed a ten-
dency for insulin resistance in PCOs patients with ≥
50 follicles.
From the reproductive hormone profile of both
study groups, an increase of LH/FSH could be appre-
ciated, with the ratio > 1. Mean reproductive hormone
profile for both groups did not exhibit any significant
differences. This was evidenced by the Mann-Whit-
ney test showing p > 0.05.
CONCLUSION
In this study of 61 patients with PCOs utilizing the
Glucose Ratio/Fasting Insulin (G:I Ratio) test me-
thod, it was found that 11 subjects (18.0%) had insu-
lin resistance whereas 50 subjects (82.0%) did not ex-
perience insulin resistance. There was a significant
relationship between fasting glucose level with the
phenomenon of insulin resistance with mean fasting
glucose level at 24.882 μU/ml.
The highest frequency of insulin resistance in this
study resided in the group categorized as overweight
as per WHO criteria (BMI 25 - 29.9 kg/m2).
RECOMMENDATIONS
All this while, one of the treatment strategies for
PCOs sufferers is the administration of Insulin-sensi-
tizing Agents such as Metformin, Rosiglitazone, and
Pioglitazone.
This study clearly demonstrated that the prevalence
of insulin resistance in PCOs patients was 18.0%.
Therefore evidently not all PCOs patients experiences
insulin resistance.
In order to provide accurate treatment to PCOs pa-
tients, it is best to perform a G:I ratio test to identify
insulin resistance prior to instituting therapy compris-
ing Insulin-sensitizing Agents.
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